explore -WSS

explore

author：comprehensive 2025-09-03 03:22:08 - browse：42948

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Beware reading your test results before your doctor does

WSS

Study fuels hope CAR

Are embryos people? Reproductive medicine's future depends on the answer

Prescription digital therapeutics are key to pharma’s future

Childhood vaccination ad campaign launches in the U.K.

Childhood vaccination ad campaign launches in the U.K.

Dexcom's push to bring CGM to type 2 diabetes patients

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Are embryos people? Reproductive medicine's future depends on the answer

Medicare proposal to cover medical devices draws a mixed reaction

Prescription digital therapeutics are key to pharma’s future

Drug repurposing or repositioning? The language matters

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Novavax promises a turnaround & Lilly roils the obesity market

CDC advisory group OKs chikungunya vaccine

hotspot

AstraZeneca lung cancer study comes in below expectations

Study fuels hope CAR

Prescription digital therapeutics are key to pharma’s future

Pfizer is about to make a big push in cancer. Will investors listen?

Study fuels hope CAR

Change Healthcare cyberattack shows risk of industry consolidation

hotspot

leisure time

hotspot

Wikipedia